B3GNTL1

Across TCGA pan-cancer cohorts, B3GNTL1 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated B3GNTL1 data layer compared with 28 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in brain lower grade glioma (LGG), where higher B3GNTL1 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated B3GNTL1 expression acts as an unfavorable survival marker, although some lineages such as SKCM and UCEC show a favorable association.

LGG, SKCM, and PRAD are the cancer types where B3GNTL1 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LGG	OS	Median	All	0.163	0.896	<.001	12	view →
SKCM	DFS	Median	II,III,IV	1.000	0.245	.010	11	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
COAD	OS	Median	III,IV	0.054	0.793	<.001	6	view →
UCEC	DFS	Median	All	1.000	0.630	.030	6	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

B3GNTL1–LGG (OS)

Open the LGG breakdown →